Stock Taper
SCREENER COMPARE ANY 2 STOCKS
NGNE
NEUROGENE INC.
NASDAQ
$36.58
▼ DOWN 3.38% (-1.28)

KEY STATISTICS

Market Cap$578.05 M
52w High$43.66
52w Low$15.93
Dividend Yield—
Frequency—
P/E-8.04
Volume132.79K
Shares Out.15.80M

COMPANY

LEADERSHIP

Rachel L. McMinn
CHIEF EXECUTIVE
Rachel L. McMinn

COMPENSATION 2026

Salary$595,000
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$7,160
Total$3,464,815

ABOUT

SECTOR
Healthcare
WENT PUBLIC
March 7, 2014
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
131

PRICE TARGET

Target High$81.00
Target Low$65.00
Target Median$70.00
Target Consensus$72.00

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.—
NOV
12
THU

SPLIT RECORD

DATETYPERATIO
2023-12-19Reverse1:4
2023-09-25Reverse1:5

PRICE

$36.58 ▼ DOWN 3.38% (−$1.28)
OVERLAYS
$36.75$37.50$38.259:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM36.58

About Neurogene Inc.

https://www.neurogene.com ↗

Neurogene Inc. develops genetic medicines for neurological diseases, including NGN-401 for Rett syndrome and NGN-101 for Batten disease, headquartered in New York.

INDUSTRY

Biotechnology

A PRODUCT NEUROGENE INC. IS KNOWN FOR

NGN-401
NGN-401

NGN-401 is an investigational AAV9 gene therapy in Phase 1/2 trials, developed by Neurogene to treat Rett syndrome with proprietary EXACT™ technology for safe, one-time MECP2 gene delivery.

COMPETITORS

COMPETITOR
ACAD COMPARE
AVXL COMPARE
PASG COMPARE
SRPT COMPARE
TSHA COMPARE

Revenue by Products

IconPRODUCTFY2024
Reportable Segment$925K

ETFS HOLDING THIS STOCK

ETFS HOLDING
75
LISTED HERE
13
RANKED BY POSITION SIZE
VTS.AX
0.00% · 619.7K
XSU.TO
0.01% · 292.4K
FESM
0.06% · 104.0K
XWEH.F
0.01% · 56.1K
AVSC
0.03% · 27.2K
R2US.L
0.02% · 24.7K
SBIO
0.30% · 19.6K
DFMC
0.01% · 13.6K
BBC
0.78% · 10.8K
RSSL
0.01% · 5.4K
HELX
0.25% · 2.1K
IBBQ
0.04% · 991
BIB
0.02% · 566

INSTITUTIONAL OWNERSHIP

SHARES OWNED
84.00%
HOLDERS
115
TOP 12 OF 115 · RANKED BY POSITION SIZE
Samsara Biocapital, LLC
1.7M sh · $34.62M
Redmile Group, LLC
1.5M sh · $29.43M
Casdin Capital, LLC
1.4M sh · $28.63M
Blackrock Inc.
1.4M sh · $50.75M
Rtw Investments, LP
1.4M sh · $23.61M
Ecor1 Capital, LLC
1.3M sh · $22.03M
Blackrock, Inc.
1.0M sh · $20.26M
Baker Bros. Advisors LP
991.7K sh · $20.43M
Balyasny Asset Management L.P.
718.4K sh · $14.48M
Toronto Dominion Bank
681.3K sh · $13.74M
Vanguard Group Inc
656.6K sh · $13.53M
Arrowmark Colorado Holdings LLC
595.8K sh · $10.33M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
DIRECTOR, OFFICER: PRESIDENT AND CFO
Cvijic Christine Mikail
Sale · 600 shares
2026-07-06
★
DIRECTOR, OFFICER: PRESIDENT AND CFO
Cvijic Christine Mikail
Sale · 4.2K shares
2026-07-07
★
DIRECTOR, OFFICER: PRESIDENT AND CFO
Cvijic Christine Mikail
Sale · 739 shares
2026-07-01
★
DIRECTOR, OFFICER: PRESIDENT AND CFO
Cvijic Christine Mikail
Sale · 2.5K shares
2026-07-02

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
3 GRADES IN THE LAST 12 MONTHS
Canaccord Genuity BUY Guggenheim BUY HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
ALMS$22.38COMPARE
SLDB$9.77COMPARE
AUTL$2.34COMPARE
OCGN$1.32COMPARE
BNTC$12.47COMPARE
FULC$3.85COMPARE
QSI$0.78COMPARE
ADCT$1.14COMPARE